Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details)

v2.4.1.9
Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Mar. 31, 2013
Aug. 31, 2013
Intangible assets:          
Goodwill $ 224,292,000us-gaap_Goodwill [1] $ 226,373,000us-gaap_Goodwill [1] $ 80,450,000us-gaap_Goodwill    
OPKO Renal          
Business Acquisition [Line Items]          
Current assets       1,224,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
[2]  
Intangible assets:          
Total intangible assets       191,740,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
Goodwill 2,411,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
    2,411,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
Property, plant and equipment       306,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
Other assets       0us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
Accounts payable and accrued expenses       (1,069,000)opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccountsPayableAndAccruedExpenses
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
Deferred tax liability       0us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
Total purchase price       194,612,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
Current Asset include cash       400,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
 
OPKO Renal | Patents          
Intangible assets:          
Patents       210,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember
 
OPKO Renal | In process research and development          
Intangible assets:          
In-process research and development       191,530,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InProcessResearchAndDevelopmentMember
 
OPKO Biologics          
Business Acquisition [Line Items]          
Current assets         21,500,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
[2]
Intangible assets:          
Total intangible assets         590,200,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
Goodwill         139,784,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
Property, plant and equipment         1,057,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
Other assets         371,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
Accounts payable and accrued expenses         (9,866,000)opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccountsPayableAndAccruedExpenses
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
Deferred tax liability         (156,403,000)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
Total purchase price         586,643,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
Current Asset include cash         20,500,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
OPKO Biologics | Patents          
Intangible assets:          
Patents         0us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember
OPKO Biologics | In process research and development          
Intangible assets:          
In-process research and development         $ 590,200,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBiologicsMember
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InProcessResearchAndDevelopmentMember
[1] As of December 31, 2014 and December 31, 2013, total assets include $7.6 million and $6.7 million, respectively, and total liabilities include $12.1 million and $10.4 million, respectively, related to SciVac, previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 4.
[2] Current assets include cash of $0.4 million and $20.5 million related to the OPKO Renal and OPKO Biologics acquisitions, respectively